SCHEMBL7205277

SCHEMBL7205277

CCN(/C(C#N)=C/C=C/c1cc(OC)c(O)cc1OC)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 3/20 0.40
SLC16A1 P53985 3/20 0.40
KMT2A Q03164 8/20 0.37
MEN1 O00255 7/20 0.37
MAPT P10636 6/20 0.37
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 2/20 0.37
RECQL P46063 1/20 0.37
TP53 P04637 1/20 0.37
CYP3A4 P08684 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
MAPK1 P28482 2/20 0.35
HPGD P15428 1/20 0.35
LMNA P02545 2/20 0.34
TUBB1 Q9H4B7 1/20 0.34
NPC1 O15118 1/20 0.34
NFKB1 P19838 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7156759 0.83 ADORA2A (0.39) SLC16A3SLC16A1KMT2AMEN1MAPT
SCHEMBL7204107 0.83 MAPT (0.42) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL7166657 0.74 TRPM8 (0.42) KMT2AMEN1MAPTKDM4ELMNA
SCHEMBL7205287 0.72 MAPT (0.47) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL7205283 0.70 KMT2A (0.56) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL4483001 0.69 KMT2A (0.46) SLC16A3SLC16A1KMT2AMEN1MAPT
SCHEMBL4487336 0.67 ALDH1A1 (0.47) SLC16A3SLC16A1KMT2AMEN1MAPT
SCHEMBL7191088 0.66 NFE2L2 (0.38) KMT2AMEN1MAPTALDH1A1EGFR
SCHEMBL7191091 0.66 NFE2L2 (0.38) KMT2AMEN1MAPTALDH1A1EGFR
SCHEMBL7156762 0.65 KIF20A (0.43) SLC16A3SLC16A1KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030109502-A1 Novel compounds for modulating cell proliferation HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) 2003-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109502-A1 Novel compounds for modulating cell proliferation MKI67, CCNA1, CCNI SLC16A3 3839/4885SLC16A1 2629/4885KMT2A 3487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.